Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review
COVID-19 is considered as the third human coronavirus and has a high potential for transmission. Fast public health interventions through antibodies, anti-virals or novel vaccine strategies to control the virus and disease transmission have been extremely followed. SARS-CoV-2 shares about 79% genomi...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2020-03-01
|
| Series: | Iranian Journal of Public Health |
| Subjects: | |
| Online Access: | https://ijph.tums.ac.ir/index.php/ijph/article/view/20537 |
| _version_ | 1811189874141691904 |
|---|---|
| author | Amirhossein SHEIKHSHAHROKH Reza RANJBAR Elnaz SAEIDI Farhad SAFARPOOR DEHKORDI Mohammad HEIAT Payam GHASEMI-DEHKORDI Hamed GOODARZI |
| author_facet | Amirhossein SHEIKHSHAHROKH Reza RANJBAR Elnaz SAEIDI Farhad SAFARPOOR DEHKORDI Mohammad HEIAT Payam GHASEMI-DEHKORDI Hamed GOODARZI |
| author_sort | Amirhossein SHEIKHSHAHROKH |
| collection | DOAJ |
| description | COVID-19 is considered as the third human coronavirus and has a high potential for transmission. Fast public health interventions through antibodies, anti-virals or novel vaccine strategies to control the virus and disease transmission have been extremely followed. SARS-CoV-2 shares about 79% genomic similarity with SARS-CoV and approximately 50% with MERS-CoV. Based on these similarities, prior knowledge in treating SARS-CoV and MERS-CoV can be used as the basis of majority of the alternatives for controlling SARS-CoV-2. Immunotherapy is an effective strategy for clinical treatment of infectious diseases such as SARS-CoV-2. Passive antibody therapy, which decreases the virus replication and disease severity, is assessed as an effective therapeutic approach to control SARS-CoV-2 epidemics. The close similarity between SARS-CoV-2 genome with the SARS-CoV genome caused both coronaviruses to bind to the same angiotensin-converting enzyme 2 (ACE2) receptors that found in the human lung. There are several strategies to develop SARS-CoV-2 vaccines, which the majority of them are based on those developed previously for SARS-CoV. The interaction between the spike (S) protein of SARS-CoV-2 and ACE2 on the host cell surface leads to the initiation of SARS-CoV-2 infection. S protein, which is the main inducer of neutralizing antibodies, has been targeted by most of these strategies. Vaccines that induce an immune response against the S protein to inhibit its binding with the host ACE2 receptor, can be considered as effective vaccines against SARS-CoV-2. Here, we aimed to review frontier therapeutics and vaccination strategies for SARS-CoV-2 (COVID-19). |
| first_indexed | 2024-04-11T14:41:05Z |
| format | Article |
| id | doaj.art-d6cab9f99bbd4b7693a22c4f46b74aff |
| institution | Directory Open Access Journal |
| issn | 2251-6085 2251-6093 |
| language | English |
| last_indexed | 2024-04-11T14:41:05Z |
| publishDate | 2020-03-01 |
| publisher | Tehran University of Medical Sciences |
| record_format | Article |
| series | Iranian Journal of Public Health |
| spelling | doaj.art-d6cab9f99bbd4b7693a22c4f46b74aff2022-12-22T04:17:58ZengTehran University of Medical SciencesIranian Journal of Public Health2251-60852251-60932020-03-0149Supple 110.18502/ijph.v49iS1.3666Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A ReviewAmirhossein SHEIKHSHAHROKH0Reza RANJBAR1Elnaz SAEIDI2Farhad SAFARPOOR DEHKORDI3Mohammad HEIAT4Payam GHASEMI-DEHKORDI5Hamed GOODARZI6Clinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, IranMolecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, IranClinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, IranHalal Research Center of IRI, FDA, Tehran, IranBaqiyatallah Research Center for Gastroenterology and Liver Disease, Baqiyatallah University of Medical Sciences, Tehran, IranCellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, IranMolecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, IranCOVID-19 is considered as the third human coronavirus and has a high potential for transmission. Fast public health interventions through antibodies, anti-virals or novel vaccine strategies to control the virus and disease transmission have been extremely followed. SARS-CoV-2 shares about 79% genomic similarity with SARS-CoV and approximately 50% with MERS-CoV. Based on these similarities, prior knowledge in treating SARS-CoV and MERS-CoV can be used as the basis of majority of the alternatives for controlling SARS-CoV-2. Immunotherapy is an effective strategy for clinical treatment of infectious diseases such as SARS-CoV-2. Passive antibody therapy, which decreases the virus replication and disease severity, is assessed as an effective therapeutic approach to control SARS-CoV-2 epidemics. The close similarity between SARS-CoV-2 genome with the SARS-CoV genome caused both coronaviruses to bind to the same angiotensin-converting enzyme 2 (ACE2) receptors that found in the human lung. There are several strategies to develop SARS-CoV-2 vaccines, which the majority of them are based on those developed previously for SARS-CoV. The interaction between the spike (S) protein of SARS-CoV-2 and ACE2 on the host cell surface leads to the initiation of SARS-CoV-2 infection. S protein, which is the main inducer of neutralizing antibodies, has been targeted by most of these strategies. Vaccines that induce an immune response against the S protein to inhibit its binding with the host ACE2 receptor, can be considered as effective vaccines against SARS-CoV-2. Here, we aimed to review frontier therapeutics and vaccination strategies for SARS-CoV-2 (COVID-19).https://ijph.tums.ac.ir/index.php/ijph/article/view/20537COVID-19;Immunotherapy;ACE2;S protein;Vaccines |
| spellingShingle | Amirhossein SHEIKHSHAHROKH Reza RANJBAR Elnaz SAEIDI Farhad SAFARPOOR DEHKORDI Mohammad HEIAT Payam GHASEMI-DEHKORDI Hamed GOODARZI Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review Iranian Journal of Public Health COVID-19; Immunotherapy; ACE2; S protein; Vaccines |
| title | Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review |
| title_full | Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review |
| title_fullStr | Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review |
| title_full_unstemmed | Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review |
| title_short | Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review |
| title_sort | frontier therapeutics and vaccine strategies for sars cov 2 covid 19 a review |
| topic | COVID-19; Immunotherapy; ACE2; S protein; Vaccines |
| url | https://ijph.tums.ac.ir/index.php/ijph/article/view/20537 |
| work_keys_str_mv | AT amirhosseinsheikhshahrokh frontiertherapeuticsandvaccinestrategiesforsarscov2covid19areview AT rezaranjbar frontiertherapeuticsandvaccinestrategiesforsarscov2covid19areview AT elnazsaeidi frontiertherapeuticsandvaccinestrategiesforsarscov2covid19areview AT farhadsafarpoordehkordi frontiertherapeuticsandvaccinestrategiesforsarscov2covid19areview AT mohammadheiat frontiertherapeuticsandvaccinestrategiesforsarscov2covid19areview AT payamghasemidehkordi frontiertherapeuticsandvaccinestrategiesforsarscov2covid19areview AT hamedgoodarzi frontiertherapeuticsandvaccinestrategiesforsarscov2covid19areview |